Regulatory approval

Published by the Health Canada.

Health Canada approved rituximab for the treatment of patients with previously untreated Stage III/IV follicular, CD20 positive, B-cell non-Hodgkin's lymphoma in combination with CVP chemotherapy.

This is written in the approval document as:

RITUXAN (rituximab for injection) is indicated for the treatment of patients with previously untreated Stage III/IV follicular, CD20 positive, B-cell non-Hodgkin's lymphoma in combination with CVP (cyclophosphamide, vincristine and prednisolone) chemotherapy.

Citation

Hoffmann-La Roche Limited. Rituxan (rituximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00071131.PDF. Revised June 2023. Accessed June 2025.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	CD20 +	Follicular Lymphoma	Cyclophosphamide, Prednisolone, Rituximab, Vincristine